Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial
Letter
[키워드] 1:1
active malignancy
acute respiratory distress syndrome
Administered
administration
age
approval
approved
ARDS
assessment
automated
Berlin
blinded
Cell
cell suspension
cellular
changes in
chronic liver disease
class
clinical
Clinical diagnosis
Clinical outcome
clinical outcomes
clinical trial
comparator
Compliance
conducted
control group
Controlled trial
COVID 19
COVID-19
COVID-19 pandemic
declined
defined
described
determine
diagnosis of COVID-19
dissemination
Donor
Dose escalation
driving
Effect
Efficacy
element
eligible
Elizabeth
enrolled
ethics committee
EudraCT
excluded
facilitate
failure
fixed dose
hospital
ICU
incidence
Inclusion
increase in
index
individual
information
infusion
intensive care unit
Intervention
Invasive mechanical ventilation
investigator
King’s College London
London
Mesenchymal stem cells
Mesenchymal stromal cells
MHRA
moderate
Mortality
MSC
MSCs
NIHR
number
objective
open label
Other
outcome
pandemic
PaO
participant
Patient
patient population
patients with ARDS
PCR test
PF ratio
Phase 1
Phase 2
Placebo
placebo-controlled
protocol
protocol amendment
Public
randomised
randomised controlled trial
REC
receiving
recruited
recruitment
repair
reported
Research
respiratory
Resuscitation
Sample size
secondary
Secondary objective
Secondary outcomes
Serious Adverse Events
severe ARDS
single intravenous infusion
SOFA
solution
Standard
steering committee
stratified
stromal cell
Study protocol
Therapeutics
therapy
trauma
Treatment
Trial
triple blinded
Trust
umbilical
United Kingdom
university
Venous Thromboembolism
Ventilation
verbal
Volume
web-based randomisation system
website
WHO
Withdrawal
[DOI] 10.1186/s13063-020-04416-w PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04416-w PMC 바로가기 [Article Type] Letter